Ovid Therapeutics

OVID

Market cap $448M

Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteers OV329 showed favorable safety, tolerability, pharmacokinetics (PK), and drug exposure at higher doses, supporting the planned advancement of Phase 2 and proof-of-concept studies Announced development expansion of OV329 into additional pediatric indications of tuberous sclerosis complex (TSC) seizures and infantile spasms (IS), conditions for which GABA-aminotransferase (GABA-AT) inhibition is a validated mechanism Strengthened balance sheet, raising $60.0 million of gross proceeds in March 2026 PIPE financing with participation from leading healthcare investors Received $53.9 million in gross proceeds upon full exercise of Series A warrants in connection with October 2025 PIPE financing Cash, cash equivalents and marketable securities were $165.6 million as of March 31, 2026, which does not include $27.3 million in proceeds received in April 2026 from exercise of Series A warrants NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including financial results for the first quarter ended March 31, 2026. “Our first quarter reflected focused execution and continued progress across our pipeline of potentially transformative small molecule medicines for intractable brain conditions,” stated Meg Alexander, President and Chief Executive Officer.

Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the Company will host a KCC2 Deep Dive R&D event highlighting its first-in-class KCC2 portfolio on Tuesday, April 14, 2026, at 9:30 am ET in New York, NY, which will also be webcast simultaneously. During the event independent expert clinicians and translational experts as well as Ovid's President and Chief Executive Officer Meg Alexander, will discuss the Company's proprietary portfolio of potential first-in-class direct activators of KCC2, including pharmacodynamic data, translational and clinical development strategy, and the potential market opportunity.

Ovid Therapeutics advances OV329, a GABA-AT inhibitor, into Phase 2 for drug-resistant adult focal onset seizures after soticlestat's failure. Recent Phase 1 data show OV329 lacks the eye toxicity seen with vigabatrin, supporting its differentiated safety profile. Management secured $60M PIPE financing, extending the cash runway into 2029, but a $385.7M modeled funding gap implies 11% annual dilution over six years.

Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript

OV329 may be safer and more potent than existing treatments. A $60M private placement will fund further development.

Ovid Therapeutics reported favorable topline safety and tolerability findings from a 7 mg dose cohort of OV329 for drug-resistant epilepsies.

Ovid Therapeutics (OVID) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.13 per share a year ago.

NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today provided pipeline progress and business updates, including financial results for the fourth quarter and full year ended December 31, 2025. The Company reported favorable topline safety, tolerability and pharmacokinetics (PK) findings from the 7 mg dose cohort of OV329, its next generation GABA-aminotransferase (GABA-AT) inhibitor. Additionally the Company announced it will add complementary development programs for OV329, expanding into tuberous sclerosis complex (TSC) seizures and infantile spasms (IS) which is funded by a private placement financing expected to result in gross proceeds of $60.0 million, before deducting placement agent fees and offering expenses.

NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of $60.0 million to the Company, before placement agent fees and offering expenses. The PIPE financing is expected to close on or about March 19, 2026, subject to satisfaction of customary closing conditions.